Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Products under Development by Stage of Development | 8 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Products under Development by Therapy Area | 9 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Products under Development by Indication | 10 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Products under Development by Companies | 12 | 2 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Products under Development by Universities/Institutes | 14 | 2 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Therapeutics Assessment | 16 | 4 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 20 | 10 |
| Acelot, Inc. | 20 | 1 |
| Arrien Pharmaceuticals, LLC | 21 | 1 |
| Genentech, Inc. | 22 | 1 |
| Genosco | 23 | 1 |
| H. Lundbeck A/S | 24 | 1 |
| Lead Discovery Center GmbH | 25 | 1 |
| Merck &Co., Inc. | 26 | 1 |
| Novartis AG | 27 | 1 |
| Oncodesign SA | 28 | 1 |
| Pfizer Inc. | 29 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drug Profiles | 30 | 17 |
| ALY-1337 Drug Profile | 30 | 1 |
| GNE-7915 Drug Profile | 31 | 1 |
| ODS-2005294 Drug Profile | 32 | 1 |
| ORS-1104 Drug Profile | 33 | 1 |
| PF-06447475 Drug Profile | 34 | 1 |
| Small Molecule to Inhibit LRRK2 for Parkinson's Disease Drug Profile | 35 | 1 |
| Small Molecules to Inhibit LRRK-2 for Parkinson's Disease Drug Profile | 36 | 1 |
| Small Molecules to Inhibit LRRK-2 for Parkinson's Disease Drug Profile | 37 | 1 |
| Small Molecules to Inhibit LRRK-2 for Parkinson's Disease Drug Profile | 38 | 1 |
| Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases Drug Profile | 39 | 1 |
| Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile | 40 | 1 |
| Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile | 41 | 1 |
| Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile | 42 | 1 |
| Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile | 43 | 1 |
| Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile | 44 | 1 |
| SR-9444 Drug Profile | 45 | 1 |
| TTT-3002 Drug Profile | 46 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Dormant Projects | 47 | 1 |
| Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Featured News &Press Releases | 48 | 3 |
| May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors | 48 | 1 |
| Oct 21, 2015: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago | 48 | 1 |
| Sep 09, 2014: Arrien Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B2 | 49 | 1 |
| Aug 16, 2012: Arrien Pharma s ORS-1104 Advances Into Investigational New Drug Enabling Stage | 49 | 1 |
| May 05, 2012: Arrien Pharma Provides Update on ORS-1104 for Treatment of Parkinson s disease | 50 | 1 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |